SPYRE THERAPEUTICS, INC.
9.99%
9,667,201
1636282
Jun 22, 2026
Jun 23, 2026, 09:45 PM
Reporting Persons (4)
This is a joint filing. The reported shares may overlap between reporting persons and should not be summed.
| Name | Type | % of Class | Aggregate | Sole Voting | Shared Voting |
|---|---|---|---|---|---|
| Peter Evan Harwin | Individual | 9.99% | 9,667,201 | 520,361 | 9,146,840 |
| Tomas Kiselak | Individual | 9.99% | 9,667,201 | 520,361 | 9,146,840 |
| Fairmount Funds Management LLC | Investment Adviser | 9.15% | 8,835,440 | 0 | 8,835,440 |
| Fairmount Healthcare Fund II L.P. | Partnership | 9.15% | 8,835,440 | 0 | 8,835,440 |
Disclosure Items (5)
Common Stock, $0.0001 par value
SPYRE THERAPEUTICS, INC.
221 Crescent Street, Waltham, MA, 02453
Item 3 of the Schedule 13D is hereby amended and supplemented as follows: On June 23, 2026, Fund II delivered to the Company a notice of conversion pursuant to Section 6.2 of the Certificate of Designation of Preferences, Rights and Limitations of Series B Non-Voting Convertible Preferred Stock (the "Certificate of Designation") to convert 16,667 shares of Series B Preferred Stock into 666,680 shares of Common Stock, in accordance with the terms of the Certificate of Designation. The conversion was effected for no cash consideration pursuant to the Certificate of Designation.
The information in rows 11 and 13 of each of the cover pages (including the explanatory note in the "Comments") of this Amendment No. 7 is incorporated by reference herein. Together, the Reporting Persons' securities include (i) 8,581,440 shares of Common Stock issuable upon conversion of 214,536 shares of Series A Preferred Stock subject to the 9.99% beneficial ownership limitation applied to all of the securities owned by the Reporting Persons and (ii) 228,646 shares of Common Stock issuable upon the exercise of options held by the Reporting Persons that are currently exercisable or will be exercisable within 60 days of the date of this filing. The securities exclude 5,260,360 shares of Common Stock issuable upon conversion of 131,509 shares of Series A Preferred Stock held directly by Fund II in excess of the beneficial ownership limitation of 9.99%.
The information in rows 7 through 10 of each of the cover pages of this Amendment No. 7 is incorporated by reference herein.
Item 5(c) of the Schedule 13D is hereby supplemented as follows: On June 23, 2026, Fund II sold in a block trade a total of 4,684,781 shares of Common Stock at a price of $85.31 per share.
99.1 Joint Filing Agreement 99.1 (incorporated by reference to Exhibit 99.1 of the Reporting Persons' Schedule 13D filed with the SEC on October 17, 2025).